<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125020</url>
  </required_header>
  <id_info>
    <org_study_id>2008BAI60B03</org_study_id>
    <nct_id>NCT01125020</nct_id>
  </id_info>
  <brief_title>Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      The study is designed to investigate the effect of postoperative adjuvant chemotherapy in
      prevention of tumor recurrence and metastasis for hepatocellular carcinoma after liver
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor recurrence and metastasis</measure>
    <time_frame>within the first year after liver transplantation</time_frame>
    <description>Examination of tumor recurrence include serum levels of alpha-fetoprotein(AFP), chest radiography, abdominal ultrasonography, chest or abdominal computed tomography (CT), magnetic resonance imaging (MRI) and bone scintigraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative survival</measure>
    <time_frame>within the first year after liver transplantation</time_frame>
    <description>Postoperative survival include rates of disease-free survival (DFS), overall survival(OS), tumor recurrence and death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Tumor Recurrence and Metastasis</condition>
  <condition>Survival</condition>
  <condition>Adjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>gemcitabine and oxaliplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>doxorubicin, 5-Fu and cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine and oxaliplatin</intervention_name>
    <description>Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.</description>
    <arm_group_label>gemcitabine and oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, 5-Fu and cisplatin</intervention_name>
    <description>Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.</description>
    <arm_group_label>doxorubicin, 5-Fu and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All liver transplantation patients with hepatocellular carcinoma between Dec 2008 and
             May 2010 are potentially eligible for enrollment.

        Exclusion Criteria:

          -  Age less than 18 years

          -  Treatment with other postoperative adjuvant chemotherapy

          -  Survival is less than 3 months after liver transplantation

          -  Inability to provide written informed consent prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Hai Peng, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-Yi Wu, MM</last_name>
    <phone>0086-021-63240090</phone>
    <phone_ext>3136</phone_ext>
    <email>wjy8541@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Hai Peng, MD</last_name>
      <phone>0086-021-63240090</phone>
      <phone_ext>3132</phone_ext>
      <email>pengpzh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jun-Wei Fan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dudek K, Kornasiewicz O, Remiszewski P, Kobryń K, Ziarkiewicz-Wróblewska B, Górnicka B, Zieniewicz K, Krawczyk M. Impact of tumor characteristic on the outcome of liver transplantation in patients with hepatocellular carcinoma. Transplant Proc. 2009 Oct;41(8):3135-7. doi: 10.1016/j.transproceed.2009.08.016.</citation>
    <PMID>19857695</PMID>
  </reference>
  <reference>
    <citation>Söderdahl G, Bäckman L, Isoniemi H, Cahlin C, Höckerstedt K, Broomé U, Mäkisalo H, Friman S, Ericzon BG. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int. 2006 Apr;19(4):288-94.</citation>
    <PMID>16573544</PMID>
  </reference>
  <reference>
    <citation>Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007 Apr 1;109(7):1384-90.</citation>
    <PMID>17330837</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <last_update_submitted>May 17, 2010</last_update_submitted>
  <last_update_submitted_qc>May 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shanghai First People's Hosptial</name_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

